Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Company Overview

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $13.46 to $14.47
• 50-Day Range: $9.90 to $15.71
• 52-Week Range: $4.80 to $30.40
• Volume: 373,950 shs
• Average Volume: 73,787 shs
• Market Capitalization: $1.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Gyre Therapeutics Stock Analysis - MarketRank™

Gyre Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 852nd out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Gyre Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gyre Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.30) per share.

Price to Book Value per Share Ratio

Gyre Therapeutics has a P/B Ratio of 77.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.32% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Gyre Therapeutics has recently decreased by 6.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gyre Therapeutics does not currently pay a dividend.

Dividend Growth

Gyre Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.32% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Gyre Therapeutics has recently decreased by 6.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.98

News Sentiment

Gyre Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Gyre Therapeutics this week, compared to 1 article on an average week.

Search Interest

1 people have searched for GYRE on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,424.00 in company stock.

Percentage Held by Insiders

Only 2.92% of the stock of Gyre Therapeutics is held by insiders.

Percentage Held by Institutions

Only 23.99% of the stock of Gyre Therapeutics is held by institutions.

GYRE Stock Analysis - Frequently Asked Questions

How have GYRE shares performed this year?

Gyre Therapeutics' stock was trading at $25.69 at the beginning of the year. Since then, GYRE stock has decreased by 45.4% and is now trading at $14.03.
View the best growth stocks for 2024 here.

How were Gyre Therapeutics' earnings last quarter?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) announced its earnings results on Tuesday, August, 13th. The company reported $0.01 EPS for the quarter. The company earned $25.23 million during the quarter.

When did Gyre Therapeutics' stock split?

Gyre Therapeutics's stock split on the morning of Saturday, January 1st 2000. The 15-1 split was announced on Saturday, January 1st 2000. The newly minted shares were issued to shareholders after the closing bell on Monday, February 13th 2017. An investor that had 100 shares of stock prior to the split would have 1,500 shares after the split.

Who are Gyre Therapeutics' major shareholders?

Gyre Therapeutics' top institutional shareholders include WINTON GROUP Ltd (0.02%), Bank of New York Mellon Corp (0.02%), Renaissance Technologies LLC (0.02%) and Marshall Wace LLP (0.01%).
View institutional ownership trends.

How do I buy shares of Gyre Therapeutics?

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/13/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 10/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GYRE
• Previous Symbol: NASDAQ:GYRE
• CUSIP: N/A
• CIK: 1124105
• Web: www.catalystbiosciences.com
• Phone: (619) 949-3681
• Fax: 336-480-2107
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-92,930,000.00
• Net Margins: N/A
• Pretax Margin: -63.25%
• Return on Equity: -197.57%
• Return on Assets: -88.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: $113.45 million
• Price / Sales: 11.86
• Cash Flow: $0.25 per share
• Price / Cash Flow: 56.52
• Book Value: $0.18 per share
• Price / Book: 80.00

Miscellaneous

• Outstanding Shares: 93,420,000
• Free Float: 83,013,000
• Market Cap: $1.35 billion
• Optionable: No Data
• Beta: 2.07